ArticleLife science alliance2018
Multi-region proteome analysis quantifies spatial heterogeneity of prostate tissue biomarkers.
Article in Life science alliance, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 58 citations in OpenAlex.
- Pan-Cancer Quantification of Driver Alteration Transmission Across Molecular Layers Reveals Limited Propagation to Protein Abundance.International journal of cancer · 2026Article
- Epigenetic profiling of prostate cancer reveals potential prognostic signatures.Journal of cancer research and clinical oncology · 2024Article
- Proteomic-based stratification of intermediate-risk prostate cancer patients.Life science alliance · 2024Article
- Mass spectrometry-based proteomics as an emerging tool in clinical laboratories.Clinical proteomics · 2023Review
- Resistance prediction in high-grade serous ovarian carcinoma with neoadjuvant chemotherapy using data-independent acquisition proteomics and an ovary-specific spectral library.Molecular oncology · 2023Article
- Evaluation of automatic discrimination between benign and malignant prostate tissue in the era of high precision digital pathology.BMC bioinformatics · 2023Article
- Article
- Implementing the reuse of public DIA proteomics datasets: from the PRIDE database to Expression Atlas.Scientific data · 2022Article
- Single-cell proteomics defines the cellular heterogeneity of localized prostate cancer.Cell reports. Medicine · 2022Article
- Machine learning for multi-omics data integration in cancer.iScience · 2022Review
- On the Road to Accurate Protein Biomarkers in Prostate Cancer Diagnosis and Prognosis: Current Status and Future Advances.International journal of molecular sciences · 2021Review
- Proteomic discovery of non-invasive biomarkers of localized prostate cancer using mass spectrometry.Nature reviews. Urology · 2021Review
- Review
- Imaging Mass Spectrometry-Based Proteomic Analysis to Differentiate Melanocytic Nevi and Malignant Melanoma.Cancers · 2021Article
- Growth and differentiation factor 15 and NF-κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection.Cancer medicine · 2021Article
- Magnetic Resonance Imaging Based Radiomic Models of Prostate Cancer: A Narrative Review.Cancers · 2021Review
- Classification of colorectal tissue images from high throughput tissue microarrays by ensemble deep learning methods.Scientific reports · 2021Article
- Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management.Clinical proteomics · 2020Review
- Spatially resolved analysis of FFPE tissue proteomes by quantitative mass spectrometry.Nature protocols · 2020Article
- Inferring clonal composition from multiple tumor biopsies.NPJ systems biology and applications · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 4 countries.
Funding
Abstract
It remains unclear to what extent tumor heterogeneity impacts on protein biomarker discovery. Here, we quantified proteome intra-tissue heterogeneity (ITH) based on a multi-region analysis of prostate tissues using pressure cycling technology and SWATH mass spectrometry. We quantified 6,873 proteins and analyzed the ITH of 3,700 proteins. The level of ITH varied depending on proteins and tissue types. Benign tissues exhibited more complex ITH patterns than malignant tissues. Spatial variability of ten prostate biomarkers was validated by immunohistochemistry in an independent cohort (n=83) using tissue microarrays. PSA was preferentially variable in benign prostatic hyperplasia, while GDF15 substantially varied in prostate adenocarcinomas. Further, we found that DNA repair pathways exhibited a high degree of variability in tumorous tissues, which may contribute to the genetic heterogeneity of tumors. This study conceptually adds a new perspective to protein biomarker discovery: it suggests that recent technological progress should be exploited to quantify and account for spatial proteome variation to complement biomarker identification and utilization.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.